Please use this identifier to cite or link to this item:
http://hdl.handle.net/11434/2232
Title: | Circulating Tumor DNA (ctDNA) as a marker of residual disease and recurrence risk in resected stage I IV epithelial ovarian cancer (EOC). |
Epworth Authors: | Ananda, Sumitra |
Other Authors: | Hong, Wei Richardson, Gary Lombard, Janine Goss, Geraldine Mileshkin, Linda Steer, Christopher O’Broin Lennon, Anne Marie McNally, Orla Douville, Christopher Popoli, Maria Ptak, Janine Silliman, Natalie Dobbyn, Lisa Papadopoulos, Nicholas Kinzler, Kenneth Vogelstein, Bert Tie, Jeanne Gibbs, Peter |
Keywords: | Epithelial Ovarian Cancer EOC Relapse Chemotherapy Detectable ctDNA Minimal Residual Disease MRD Recurrence Recurrence Free Survival RFS Neoadjuvant Therapy Post Adjuvant Chemotherapy |
Issue Date: | Oct-2023 |
Conference Name: | Epworth HealthCare Research Month 2023 |
Conference Location: | Epworth Research Institute, Victoria, Australia |
Abstract: | Patients with epithelial ovarian cancer (EOC) often relapse despite surgery and chemotherapy. Current prognosis estimates, based on FIGO staging molecular features lack precision. Standard of care for stage I III EOC is 6 cycles of adjuvant chemotherapy, which may include 3 cycles of neoadjuvant treatment. Many treated patients do not benefit from chemotherapy because they had no residual disease post operatively or because treatment did not eradicate disease that was present. Studies in multiple solid tumor types have demonstrated that after curative intent surgery detectable ctDNA a marker of minimal residual disease (MRD) predicts a very high risk of recurrence. Our primary aim was to explore the association between detectable ctDNA following debulking of primary EOC and recurrence free survival (RFS). Secondary aims included exploring the relationship between ctDNA and RFS at EOC diagnosis, following neoadjuvant therapy and post adjuvant chemotherapy. In a prospective cohort of patients with epithelial ovarian cancer analysed for ctDNA Neoadjuvant therapy cohort - ctDNA was detectable pre treatment in most patients. Most pre treatment ctDNA ve patients remained ctDNA ve despite chemotherapy. Post cancer cytoreduction surgery cohort - ctDNA was more likely to be detected in patients with stage III/IV disease, those with residual disease, and those without a BRCA mutation. ctDNA detection was associated with 2 year RFS. Post adjuvant chemotherapy cohort - ctDNA detection was associated with a trend to inferior 2 year RFS. |
URI: | http://hdl.handle.net/11434/2232 |
Type: | Conference Poster |
Affiliated Organisations: | Walter and Eliza Hall Institute of Medical Research, Australia Peter MacCallum Cancer Centre, Australia Western Health, Australia Department Of Medicine, University of Melbourne, Australia Cabrini Health, Australia Newcastle Private, Australia John Hopkins University, School of Medicine, USA Monash Medical Centre, Australia Eastern Health, Australia Mercy Hospital for Women, Heidelberg, Australia Border Medical Oncology, Australia Royal Women’s Hospital Parkville, Australia |
Type of Clinical Study or Trial: | Prospective Observational Study |
Appears in Collections: | Research Week |
Files in This Item:
File | Description | Size | Format | |
---|---|---|---|---|
ASCO Poster ctDNA Ovary Final 01082023 Epworth Research Week _SAnanda.pdf | 543.35 kB | Adobe PDF | View/Open |
Items in Epworth are protected by copyright, with all rights reserved, unless otherwise indicated.